JPS58116416A - 心筋梗塞治療剤 - Google Patents
心筋梗塞治療剤Info
- Publication number
- JPS58116416A JPS58116416A JP22575282A JP22575282A JPS58116416A JP S58116416 A JPS58116416 A JP S58116416A JP 22575282 A JP22575282 A JP 22575282A JP 22575282 A JP22575282 A JP 22575282A JP S58116416 A JPS58116416 A JP S58116416A
- Authority
- JP
- Japan
- Prior art keywords
- dogs
- calcium
- cardiac disease
- disease therapy
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000019622 heart disease Diseases 0.000 title claims description 4
- 208000020446 Cardiac disease Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000011575 calcium Substances 0.000 description 14
- 229910052791 calcium Inorganic materials 0.000 description 14
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 13
- 241000282472 Canis lupus familiaris Species 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 7
- 210000002751 lymph Anatomy 0.000 description 7
- 206010011086 Coronary artery occlusion Diseases 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 210000001365 lymphatic vessel Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 238000002587 lymphangiography Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- QVJOCVAHLQXBHC-UHFFFAOYSA-L OC1(CC=C(C=C1)O)S(=O)(=O)[O-].[Ca+2].OC1(CC=C(C=C1)O)S(=O)(=O)[O-] Chemical class OC1(CC=C(C=C1)O)S(=O)(=O)[O-].[Ca+2].OC1(CC=C(C=C1)O)S(=O)(=O)[O-] QVJOCVAHLQXBHC-UHFFFAOYSA-L 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000032630 lymph circulation Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33367181A | 1981-12-23 | 1981-12-23 | |
| US333671 | 1994-11-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58116416A true JPS58116416A (ja) | 1983-07-11 |
| JPH0378364B2 JPH0378364B2 (https=) | 1991-12-13 |
Family
ID=23303775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP22575282A Granted JPS58116416A (ja) | 1981-12-23 | 1982-12-22 | 心筋梗塞治療剤 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS58116416A (https=) |
| IT (1) | IT1212555B (https=) |
-
1982
- 1982-12-21 IT IT8249714A patent/IT1212555B/it active
- 1982-12-22 JP JP22575282A patent/JPS58116416A/ja active Granted
Non-Patent Citations (1)
| Title |
|---|
| CHEM.ABSTR=1972 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0378364B2 (https=) | 1991-12-13 |
| IT8249714A0 (it) | 1982-12-21 |
| IT1212555B (it) | 1989-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1744739B1 (en) | Use of treprostinil to treat neuropathic diabetic foot ulcers | |
| Gueron et al. | Severe myocardial damage and heart failure in scorpion sting: Report of five cases | |
| Damato | Diphenylhydantoin: Pharmacological and clinical use | |
| Shimada et al. | Arrhythmia during insulin-induced hypoglycemia in a diabetic patient | |
| JPH04506667A (ja) | 甲状腺ホルモン心臓治療 | |
| Gould et al. | Treatment of cardiac arrhythmias with phentolamine | |
| Youmans et al. | Neosynephrine in treatment of paroxysmal supraventricular tachycardia | |
| McDevitt et al. | The uterine and cardiovascular effects of salbutamol and practolol during labour | |
| JPS6129927B2 (https=) | ||
| Kerr et al. | Quinidine overdose. Neurological and cardiovascular toxicity in a normal person | |
| Hooqenhuvze et al. | Acute effects of intravenous amiodarone in patients with complex ventricular dysrhythmias | |
| Holt et al. | Intravenous amiodarone; An effective anti-arrhythmic agent | |
| JPS58116416A (ja) | 心筋梗塞治療剤 | |
| Nathanson | Pathology and pharmacology of cardiac syncope and sudden death | |
| Grondin et al. | Evaluation of cardiac drugs in the presence of an electrical pacemaker | |
| Bellet et al. | Effect of molar sodium lactate in increasing cardiac rhythmicity: Clinical and experimental study of its use in the treatment of patients with slow heart rates, Stokes-Adams syndrome, and episodes of cardiac arrest | |
| Schoonmaker et al. | Treatment of tachyarrhythmias and bradyarrhythmias by cardiac sympathectomy and permanent ventricular pacing | |
| RU2045961C1 (ru) | Способ проведения коронарографии в эксперименте | |
| Peters et al. | Continuous intravenous administration of histamine: effect on the electrocardiogram and serum potassium | |
| Minuck | The chemotherapy of cardiac arrest | |
| Waldman | The treatment of angina pectoris with testosterone propionate | |
| Jackson | The General Pharmacologic Action of a New Vasopressor Drug, EA-83 (2-Methylamino-6-Hydroxy-6-Methyl Heptane, 2-Methylamino Iso-Octanol). | |
| NATHANSON | Rhythmic property of the human heart | |
| US3849570A (en) | Method of treating cardiac arrhythmia with 2-(2'-diethylaminoethyl)-3-phenyl-phthalimidine and its salts | |
| Linenthal et al. | Sinoauricular nodal depression and atrioventricular nodal rhythm due to quinidine: Report of a proved case |